Lastly, we demonstrated that shikonin treatment in vitro leads to a loss of OXPHOS activity, bioenergetic dysfunction, and death of SDHA- and LRPPRC-overexpressing ovarian cancer cell lines. The gene discussed is SDHA; the disease is ovarian carcinoma.